List view / Grid view
27 January 2016 | By Victoria White
Results from the LUX-Lung 7 trial demonstrated superiority in progression-free survival and time to treatment failure with Boehringer Ingelheim’s Giotrif/Gilotrif (afatinib) versus Iressa (gefitinib)...
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
26 January 2016 | By Victoria White
Researchers from UCL found the anti-convulsant drug phenytoin protected neural tissue in patients with optic neuritis - often the first symptom of MS...
26 January 2016 | By Victoria White
The FDA has accepted a sNDA for Jardiance (empagliflozin) based on cardiovascular risk reduction data from the EMPA-REG OUTCOME trial...
26 January 2016 | By Victoria White
Humira (adalimumab) is an anti-TNF-α monoclonal antibody which is approved in many regions for the treatment of several inflammatory diseases...
25 January 2016 | By Victoria White
The purpose of the study is to establish a dosing regimen for this combination therapy and assess its safety and efficacy...
25 January 2016 | By Tecan
Tecan has launched the Spark® 20M multimode microplate reader, offering tailor-made solutions to suit virtually any drug discovery or advanced life science research application...
25 January 2016 | By Victoria White
IX-01 is an oral oxytocin receptor antagonist being developed for the treatment of premature ejaculation...
25 January 2016 | By Victoria White
Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA in October last year...
25 January 2016 | By Victoria White
Ninlaro (ixazomib) was recently approved by the FDA, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma...
25 January 2016 | By Victoria White
The FDA has approved Opdivo (nivolumab) + Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma...
25 January 2016 | By Victoria White
Amgen has announced results from a study of Vectibix and best supportive care in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC)...
25 January 2016 | By Victoria White
Celgene has announced results from multiple analyses evaluating second-line treatments following Abraxane and gemcitabine (AG) in metastatic pancreatic cancer patients.
22 January 2016 | By Victoria White
GlobalData states that the impressive growth will primarily be driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents...
22 January 2016 | By Victoria White
The EC has approved the Type II variation for Adcetris to include data on the retreatment of adult patients with R/R Hodgkin lymphoma or R/R sALCL who previously responded to Adcetris and who later relapse....
